deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT04439006

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In

Sponsor: Janssen Scientific Affairs, LLC

Conditions Aplastic Anemia Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Monoclonal B-Cell Lymphocytosis Monoclonal Gammopathy of Undetermined Significance Myelodysplastic Syndrome Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions Best Practice Ibrutinib
Updated 10 times since 2020 Last updated: Dec 19, 2023 Started: Oct 23, 2020 Primary completion: Sep 20, 2022 Completion: Sep 20, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04439006, this PHASE1 trial focuses on Aplastic Anemia and Hematopoietic and Lymphoid Cell Neoplasm and remains completed. Sponsored by Janssen Scientific Affairs, LLC, it has been updated 10 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshotNot Yet Recruiting~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshotNot Yet Recruiting~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotRecruiting~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotRecruiting~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshotRecruiting~Mar 2022 – ~May 2023 · 14 months · monthly snapshotActive Not Recruiting~May 2023 – ~Jan 2024 · 8 months · monthly snapshotActive Not Recruiting~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed · Phase: PHASE2 → PHASE1

  4. May 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 5 earlier versions

  1. Oct 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  2. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Scientific Affairs, LLC
  • Jennifer Woyach
Data source: Ohio State University Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations